Bayer bets $547M on therapies for RNA-driven cancers

seekingalpha08-29

Bayer (OTCPK:BAYZF) has decided to pay Boston, Massachusetts-based biotech NextRNA Therapeutics up to $547M for two therapeutic programs targeted at long non-coding RNA (lncRNA)- driven cancers. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2463232526?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1302299365/image_1302299365.jpg","is_english":true,"pubTime":"2024-08-29 19:58","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2463232526","market":"nz","top_or_hot":-1,"title":"Bayer bets $547M on therapies for RNA-driven cancers","media":"seekingalpha","content":"<div>\n<p>Bayer (OTCPK:BAYZF) has decided to pay Boston, Massachusetts-based biotech NextRNA Therapeutics up to $547M for two therapeutic programs targeted at long non-coding RNA (lncRNA)- driven cancers. The ...</p>\n\n<a href=\"https://seekingalpha.com/news/4145018-bayer-bets-547m-therapies-rna-driven-cancers\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer bets $547M on therapies for RNA-driven cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer bets $547M on therapies for RNA-driven cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-29 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4145018-bayer-bets-547m-therapies-rna-driven-cancers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bayer (OTCPK:BAYZF) has decided to pay Boston, Massachusetts-based biotech NextRNA Therapeutics up to $547M for two therapeutic programs targeted at long non-coding RNA (lncRNA)- driven cancers. The ...</p>\n\n<a href=\"https://seekingalpha.com/news/4145018-bayer-bets-547m-therapies-rna-driven-cancers\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://seekingalpha.com/news/4145018-bayer-bets-547m-therapies-rna-driven-cancers","article_id":"2463232526","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1302299365/image_1302299365.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2463232526","pubTimestamp":1724932687,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Bayer  has decided to pay Boston, Massachusetts-based biotech NextRNA Therapeutics up to $547M for two therapeutic programs targeted at long non-coding RNA - driven cancers. The payment, made up of upfront and near-term milestones as well as sales-related royalties, is part of a collaboration and licensing deal between Bayer  and NextRNA for small molecule therapies targeting lncRNAs in cancer.  According to its terms, Bayer  gets access to NextRNA’s approach to inhibit lncRNAs, a group of therapeutic targets that cause diseases through the involvement of RNA-binding proteins . Out of the two jointly conducted programs, one is still in early preclinical development at NextRNA, while the other is still under investigation for specific lncRNA targets, one of which the German pharma giant will have the option to select.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BAYZF":"Bayer A.G.","RNA":"Avidity Biosciences, Inc.","BK4007":"制药","BAYRY":"Bayer A.G."},"translate_title":"拜耳押注5.47亿美元用于RNA驱动的癌症疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":1,"BAYZF":1,"RNA":1},"content_text":"Bayer (OTCPK:BAYZF) has decided to pay Boston, Massachusetts-based biotech NextRNA Therapeutics up to $547M for two therapeutic programs targeted at long non-coding RNA (lncRNA)- driven cancers. The payment, made up of upfront and near-term milestones as well as sales-related royalties, is part of a collaboration and licensing deal between Bayer (OTCPK:BAYRY) and NextRNA for small molecule therapies targeting lncRNAs in cancer.  According to its terms, Bayer (OTCPK:BAYRY) gets access to NextRNA’s approach to inhibit lncRNAs, a group of therapeutic targets that cause diseases through the involvement of RNA-binding proteins (RBPs). Out of the two jointly conducted programs, one is still in early preclinical development at NextRNA, while the other is still under investigation for specific lncRNA targets, one of which the German pharma giant will have the option to select.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2463232526"}